|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Singular Genomics Systems, Inc. (OMIC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
71,560,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Singular Genomics Systems is a life science technology company that is utilizing next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians. Co. has developed a proprietary NGS technology, which it refers to as its Sequencing Engine. Co.'s primary product, the G4, targets the NGS market and is comprised of an instrument and associated menu of consumable kits. Co.'s second product in development, the PX, combines single-cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to provide a versatile multiomics solution.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
318,468 |
488,468 |
565,302 |
| Total Buy Value |
$0 |
$135,252 |
$274,176 |
$462,728 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
3 |
4 |
6 |
| Total Shares Sold |
0 |
0 |
631,648 |
631,648 |
| Total Sell Value |
$0 |
$0 |
$361,987 |
$361,987 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
3 |
3 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ropp Sam |
Chief Commercial Officer |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,187 |
16,750 |
|
- |
|
| Meeter Dalen |
Chief Financial Officer |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
200,273 |
|
- |
|
| Glezer Eli N. |
Chief Scientific Officer |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
4,585,000 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2024-03-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,583 |
4,090,372 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2024-03-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,583 |
9,766 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,583 |
24,349 |
|
- |
|
| Ropp Sam |
Chief Commercial Officer |
• – – |
2023-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,188 |
12,563 |
|
- |
|
| Meeter Dalen |
Chief Financial Officer |
• – – |
2023-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
194,023 |
|
- |
|
| Glezer Eli N. |
Chief Scientific Officer |
• – – |
2023-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
4,577,500 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-12-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,583 |
4,075,789 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,583 |
9,766 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,583 |
24,349 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-11-17 |
4 |
B |
$0.42 |
$31,755 |
I/I |
75,000 |
4,061,206 |
2.66 |
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-11-16 |
4 |
B |
$0.41 |
$17,857 |
I/I |
43,468 |
3,986,206 |
2.58 |
- |
|
| Glezer Eli N. |
Chief Scientific Officer |
• – – |
2023-11-16 |
4 |
B |
$0.43 |
$85,640 |
D/D |
200,000 |
4,570,000 |
2.74 |
- |
|
| Ghai Jyotsna |
Chief Operating OfficerOfficer |
• – – |
2023-11-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,000 |
|
- |
|
| Ropp Sam |
Chief Commercial Officer |
• – – |
2023-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,187 |
8,375 |
|
- |
|
| Meeter Dalen |
Chief Financial Officer |
• – – |
2023-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
187,771 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-09-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,584 |
3,942,738 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-09-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,584 |
9,766 |
|
- |
|
| Spaventa Andrew |
Chief Executive Officer |
• • – |
2023-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,584 |
24,350 |
|
- |
|
| Glezer Eli N. |
Chief Scientific Officer |
• – – |
2023-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
4,370,000 |
|
- |
|
| Kamdar Kim P. |
Director |
– • – |
2023-08-15 |
4 |
S |
$0.53 |
$106,960 |
I/I |
(200,000) |
3,763,985 |
|
- |
|
| Kamdar Kim P. |
Director |
– • – |
2023-08-14 |
4 |
S |
$0.57 |
$44,424 |
I/I |
(77,991) |
3,963,985 |
|
- |
|
| Kamdar Kim P. |
Director |
– • – |
2023-08-11 |
4 |
S |
$0.60 |
$210,603 |
I/I |
(353,657) |
4,041,976 |
|
- |
|
49 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
